| By Aesica Pharmaceuticals |
| Friday, 19 March 2010 |
 |
Aesica Pharmaceuticals, an innovative, flexible and service-driven
|
|
supplier of Active Pharmaceutical Ingredients (APIs), finished dosage forms and custom synthesis solutions, is pleased to announce that the company has won a place in the latest issue of Deloitte Buyout Track 100 published in The Sunday Times.
The Buyout Track 100 league table ranks the top 100 private equity-owned British firms, based on their EBITDA growth over the past years.
Buyout Track 100 is compiled by Fast Track, the Oxford-based networking events and research company that |
|
|
ranks Britain's top private companies and provides networking opportunities for entrepreneurs.
Since its foundation in 2004, Aesica experienced significant growth through successive acquisitions of facilities from leading pharmaceutical companies in response to the trend towards outsourcing of manufacturing across the pharmaceutical industry.
Over the last few years Aesica more then trebled in size and built a customer base that includes the world ‘s largest pharmaceutical companies, leading generic manufacturers and emerging pharma companies.
Dr. Robert Hardy, CEO of Aesica, said: "Inclusion in the Buyout Track 100 is recognition of the hard work and dedication of our staff over the past |
|
six years and of the progress we have made in delivering our vision.
Throughout this period of rapid growth and development we have enjoyed the support of our major sharehol der LDC."
For further information :
Aesica PDF Brochure
Active Pharmaceutical Ingredients (APIs)
Formulations
Custom synthesis
Contract manufacturing
Process development and scale-up
Aesica Pharmaceuticals Limited
Quorum 5
Balliol Business Park East
Benton Lane
Newcastle upon Tyne
NE12 8EZ
United Kingdom
T: +44 (0)191 218 1960
F: +44 (0)191 266 9447
info@aesica-pharma.com
|
|
|
